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Vigabatrin (VGB) has been shown through several studies to be safe and effective as add-on therapy, particularly 
for the treatment of partial seizures in patients with severe epilepsies followed for years in hospital-based clinics. 
We now report additional clinical experience with VGB arising from an open trial of add-on VGB therapy in 
patients with relatively few seizures followed by qualified neurologists in private practice (the French Neurologists 
Sabril@ Study Group). VGB was administered to 397 patients aged 12-74 years (mean age = 37.5 f 13.8 years) who 
presented with no more than seven partial seizures of any type per month during a 3-month baseline period (mean 
number of seizures = 3.7 f 1.9/month). 
Simple partial seizures were reported in 121 (30.5%) patients, complex partial seizures in 282 (71.0%) and 
seizures with secondary generalization were reported in 111 (28.0%). The mean number of associated antiepileptic 
drugs (AEDs) was 1.9 f 0.9 and the mean dose of VGB was 2.21 f 0.64 g/day. Following introduction of VGB, 53 
(13.4%) became seizure-free and remained so during the whole trial. During the fourth month of treatment, 158 
patients (39.8%) had no seizures at all and a further 69 (17.4%) had their seizure frequency reduced by more than 
50%. Secondary generalization was controlled during the whole period of treatment in 5.5 out of 97 patients 
(56.7%), 17 of which remained free of all types of partial seizures. VGB showed a good tolerability profile; adverse 
experiences more frequently reported were drowsiness and sleep disturbances. No action was necessary in the great 
majority of cases; the dose was reduced in 26 (6.5%) and VGB was discontinued in 32 (8%) patients. 
These data provide additional evidence that VGB can be used safely early on to treat patients with mild to 
moderate partial epilepsies. Secondary generalization was controlled in the majority of patients. Factors associated 
with the everyday clinical use of VGB, that resulted from a series of organized meetings with the investigators, are 
discussed. 
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INTRODUCTION 
The GABAergic system is thought to play an 
important role in the origin and spread of 
epileptic seizures. The therapeutic action of 
vigabatrin (VGB) is considered to be mediated by 
the GABAergic system, by irreversible inhibition 
of GABA-transaminase activity’. Such inhibition 
results in a 2 to 3-fold elevation of GABA levels 
in cerebrospinal fluid (CSF), indicating that the 
drug penetrates into the central nervous system 
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(CNS)‘. Clinical experience with VGB (Sabril@) 
has mainly been gained in Europe, where the first 
encouraging single-blind studies were published 
in 1983374 and the drug has been licensed in many 
countries since 1989. 
Although controlled studies are valuable in 
demonstrating statistically significant efficacy for 
a given drug, they do not always reflect everyday 
clinical practice. These classical studies on new 
antiepileptic drugs (AEDs) are usually carried 
out in specialist departments for the tertiary 
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referral of AED-resistant patients and often 
include those for whom surgery has been 
unsuccessful. Historically, publications on the use 
of VGB have mainly concerned patients with 
chronic epilepsy, usually having a substantial 
number of seizures per month and receiving 
polytherapy. Most of the patients included in 
clinical trials were followed in hospital-based 
clinics or lived in institutions. In this type of 
patient, the value of VGB as add-on therapy for 
the treatment of intractable drug-resistant epi- 
lepsies has been showr?. In both adults and 
children, the best indication has proved to be 
epilepsies with partial seizures. Recent studies 
suggest that VGB may also be especially valuable 
in the management of infantile spasms’6*17. 
Experience from more than 10 years of clinical 
use has demonstrated that VGB has a favourable 
tolerability protile, being associated with a 
remarkably low incidence of adverse effects3-18. 
The aim of the present study was to explore 
prospectively the efficacy, tolerability and ease of 
use of VGB in a patient population that was 
larger and more representative of patients seen in 
routine practice than those of previous studies. 
These patients often have less frequent seizures, 
are usually out-patients who have not warranted 
referral to tertiary epilepsy units and are there- 
fore excluded from controlled studies. In a recent 
study, it was suggested that this type of patient 
may be even more responsive to VGB than 
patients with chronic refractory epilepsy. 
METHODS 
The study population consisted of patients aged 
between 12 and 74 years, who presented with 
between one and seven partial seizures of any 
type per month. Patients with a diagnosis of 
primary generalized epilepsy (ILAE Classifica- 
tion) were excluded. Participating investigat- 
ors were all quantified neurologists (French 
Neurologists Sabril@ Study Group) in private 
practice. 
The 4-month study employed a multicentre, 
prospective, open design. After an initial 3-month 
baseline period, patients received VGB as add-on 
therapy; the initial dose was 2 g/day, given in two 
doses. The investigator had the authority to 
introduce the whole dose from day 1 or to 
introduce it over the course of 1 week. The drug 
was provided by Marion Merrell Dow as standard 
vigabatrin 500 mg tablets and was delivered by 
the investigator. Doses of concomitant anticon- 
vulsant medications were kept constant through- 
out the study. 
Patients were asked to keep a detailed record 
of seizures during the trial. Follow-up visits were 
scheduled at weeks 0, 2, 6 and 17. A detailed 
clinical and neurological examination and an 
evaluation of weight, arterial pressure and cardiac 
parameters were carried out at the inclusion visit 
(week 0) and on week 17. Both clinical evalua- 
tions were coupled to an EEG and laboratory 
tests, including haemoglobin, haematocrit, red 
and white blood cell count, platelet count, serum 
glucose, creatinine, uric acid, liver transaminases 
and gamma-glutamyltransferase. 
Patients were instructed to report all adverse 
reactions that occurred during the study period, 
regardless of whether they were thought to be 
associated with VGB. If signs of VGB in- 
tolerance occurred, the investigator could reduce 
the initial 2g/day dose to 1.5 g/day. After 4 
weeks of treatment at the recommended 2 g/day 
regimen, the investigator would increase the dose 
of VGB progressively, if this was clinically 
necessary. Investigators were advised to perform 
the dose adjustment in 0.5 g increments up to a 
maximum dose of 4g/day. A 7-day interval was 
to be respected between dose adjustments. 
The protocol was approved by an Ethics 
Committee and each patient provided informed 
consent before inclusion in the study. 
To ensure uniformity of evaluation across all 
study sites, for both efficacy and tolerability 
criteria, all investigators were invited to attend 
one of the 12 study result review meetings that 
were organized by the study co-ordinator and the 
study sponsor. In discussing the results with the 
investigators, our objective was to avoid losing 
clinical experience with individual patients 
amongst the total study population. 
RESULTS 
The demographic characteristics of the 397 
patients included are summarized in Table 1. The 
mean number of anticonvulsant drugs per patient 
Table 1: Demographic characteristics 
Male patients 183 
Female patients 214 
Total number of patients 397 
Mean age (years) 37.5 (range, 12-74) 
Mean duration of epilepsy (years) 21 (range, l-63) 
Mean age at onset of seizures (years) 17.5 (range, O-69) 
Mean number of concomitant AEDs 1.9 oer oatient 
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Table 2: Concomitant anticonvulsant medication 
AED n Mean dose sd Range 
(mg) 
seizure frequency after 4 months of treatment. 
Fifty-three patients (13.4%) remained seizure- 
free for the duration of the trial, since 
introduction of VGB. 
Carbamazepine 
Valproate 
Phenobarbital 
Clonazepam 
Phenytoin 
Phenobarbital 
259 840.2 328.3 200-2000 
148 1563.2 588.6 200-3000 
98 127.3 55.3 IO-300 
53 5.3 6.9 0.5-30 
45 232.3 99.4 30-500 
(+ caffeine) 
Clobazam 
Phenobarbital 
43 266.9 754.8 5-500 
37 20.1 13.9 5-60 
(+ amphetamine) 33 112.4 46.5 10-200 
Analysis of efficacy with respect to seizure type 
revealed that VGB was particularly effective in 
patients with secondary generalization (Fig. 1). 
Indeed, 84.7% and 78.4% of patients were free 
from this type of seizure during the first and 
fourth months of treatment, respectively. Secon- 
dary generalization was completely controlled 
throughout the trial in 55 patients out of 97 
(56.7%), of whom 17.5% were free of all types of 
partial seizures. 
was 1.9 (Table 2) and 34.7% of patients received 
monotherapy. Most of the patients received 
combinations of AEDs such as carbamazepine 
(259 patients, mean dose 840mg/day), 
phenobarbital (174 patients, mean dose 
169 mg/day) or sodium valproate (148 patients, 
mean dose 1563 mg/day). 
Taking into account the type of patients 
included in this study, we considered it useful to 
re-analyse efficacy results in the 369 patients who 
had received at least 30 days of treatment with 
VGB. This second analysis permits-evaluation of 
results in line with clinical practice (Fig. 2). 
During the baseline period, the mean number 
of seizures per month was 3.7 f 1.9. Simple 
partial seizures were reported in 121 (30.5%), 
complex partial seizures in 282 (71.0%) and 
seizures with secondary generalization in 111 
(28.0%). 
The mean duration of treatment was 112.4 f 
35.3 days. The mean final dose of VGB was 
2.21 f 0.64 g/day and 64.2% were maintained on 
the initial 2 g/day dose. 
Efficacy and tolerability were analysed on an 
intention-to-treat basis. After one month of VGB 
treatment, 229 patients (57.7%) were free from 
seizures and during the fourth month, 158 
(39.8%) were seizure-free. Reasons for early 
discontinuation (less than 30 days of treatment) 
are summarized in Table 3. A further 69 patients 
(17.4%) showed a reduction in seizure frequency 
of more than 50% during the first month of VGB 
treatment; the corresponding value after 4 
months was 17.6%. Overall, therefore, 57.4% of 
patients showed at least a 50% reduction in 
Tolerability appeared good, since 206 of the 
total patients reported no treatment-related 
adverse events during the study. The remaining 
191 reported a wide range of undesirable events. 
These were assessed as certainly, probably or 
possibly related to the study drug in 16, 34.5 and 
3.7% of cases, respectively. The adverse reactions 
were assessed as mild in 54.4% of cases, moderate 
in 32.3% and severe in only 12.3% of cases. No 
special measure had to be taken in the majority 
of cases (59.1%). A reduction in VGB dosage was 
sufficient in 26 patients (6.5% of the total study 
population) and VGB had to be discontinued in 
only 32 patients (8%). 
The most frequently reported adverse events 
(Table 4) were sleep disturbances, mainly drowsi- 
ness (18% of patients), and irritability (7.1%). 
There was a trend towards weight gain in 23 
Table 3: Reasons for early discontinuation of VGB treatment 
(n = 28) 
Reason* Number of patients 
Adverse event 10 
Compliance 4 
Lack of efficacy 1 
Patient’s decision 8 
Lost to follow-up 4 
Others 9 
* Several reasons possible per patient 
1st 2nd 3rd 4th 
month month month month 
(n=lll) (n=102) (n=lOO) (n=97) 
Fig. 1: Evaluation of efficacy in the subgroup of patients 
presenting with secondarily generalized seizures. 
0, Seizure free: a. decrease by SO%; e3, decrease by 
~50%; IZi, no change or worsening. 
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Simple partial 
seizures 
Complex partial Partial with 
seizures secondary generalization 
30 days 4th 30 days 4th 30 days 4th 
(n=ll.5) month (,1=261) month (r1=l02) month 
(r1=104) (r1=242) (11=97) 
Fig. 2: Evaluation of efficacy by type of partial seizure 
during the first and fourth month in patients who received at 
least 30 days of vigabatrin (n = 369). 0, Seizure free; H, 
decrease by X0%; tZi, decrease by ~50%; a, no change or 
worsening. 
patients (5.8%). The mean weight of the patients 
increased from 67.8 kg (sd = 13.8) to 68.3 (sd = 
15.7), but this difference was not statistically 
significant. No patient had to discontinue 
treatment because of an abnormal laboratory 
value. 
The investigators decided to discontinue treat- 
ment with VGB in four patients who presented 
with mild to moderate drowsiness and in another 
three that complained of rather severe drowsi- 
ness. Irritability, together with insomnia, was 
reported by one patient and another three 
reported irritability alone. In two patients, VGB 
was discontinued rather early because of 
difficulties in concentrating. VGB treatment was 
interrupted in one patient who presented with an 
increase in seizure frequency, in two who 
presented a transitory confusional state, in one 
who reported visual hallucinations and in one 
who experienced exacerbation of associated 
myoclonias. Depression was reported by one 
patient. 
During the investigators’ discussions, mood 
alterations that occurred after the initiation of 
Table 4: Principal adverse events reported 
Adverse events II Percentage of 
patients 
Sleep disorders 73 18.4 
Irritability, nervousness 28 7.1 
Cognitive effects 18 4.5 
Mood disorders 6 1.5 
Psychic disorders 3 0.7 
Dizziness 24 6.0 
Nausea 17 4.3 
Headache 19 4.8 
Weight gain 23 5.8 
VGB were reported. These comprised both 
improvement (which is often associated with 
improved seizure control) and worsening. In six 
cases, these were mood disorders likely to be 
related to VGB treatment. One patient, who was 
receiving VGB in conjunction with phenobarbital 
and carbamazepine, attempted suicide. He had 
experienced a severe road accident, had a 
previous history of compulsive behaviour 
episodes and was mentally retarded. VGB was 
not discontinued but similar episodes were not 
reported. 
DISCUSSION 
There are many well-controlled published 
studies on the efficacy and safety” of VGB. This 
study was not designed to replicate such trials but 
to reflect clinical practice and provide neurolog- 
ists with a realistic expectation when treating 
patients on an individual basis. 
Efficacy 
Although one would predict that a drug that 
demonstrated efficacy and good tolerability when 
used in refractory epilepsies will also show good 
efficacy in less severe cases, extrapolation of 
scientific results is always difficult. 
The majority of patients included in this study 
were socially active people with relatively few 
seizures per month. Therefore, we attached 
particular attention to the percentage that re- 
mained seizure-free (13.4%) during the whole 
period following the introduction of VGB. 
Secondary generalization, a major handicap in 
socially active patients, was controlled through- 
out the study in 55 (56.7%) out of 97 patients. It is 
highly unlikely that such a result is related to a 
placebo effect. 
In most of the controlled studies concerning 
VGB, the percentage of patients that achieved a 
more than 50% reduction in seizure frequency 
was used as a criterion. In the majority of these 
studies, both in children13,‘“*‘6 and in adults5-12, 
more than 40-50% of the patients presented with 
a reduction in seizure frequency of at least 50%. 
The present study clearly demonstrates the 
efficacy of VGB in paitents with relatively rare 
partial onset seizures since during the fourth, 
month of treatment, seizure frequency was 
reduced by at least 50% in 228 patients (57.4%), 
39.8% of whom were seizure-free. If efficacy is 
assessed on the basis of the 369 patients who 
Vigabatrin in non-severe partial epilepsies 229 
received VGB for at least one month (Fig. 2), 
seizure frequency at the fourth month was 
reduced by at least 50% in nearly two-thirds of 
the patients (62%). These elements complement 
the results of previous studies on patients with 
severe epilepsies. 
After more than 10 years of clinical use, VGB 
can now be considered as an important drug in 
the treatment of partial epilepsies. Effective 
control of secondary generalization, as demon- 
strated in the present study, may prove to be an 
essential characteristic of VGB, especially with 
the large-scale introduction of the drug into 
clinical practice. 
Clinical adverse events 
Only 16% of the adverse events reported during 
the study were considered by the investigator to 
be definitely related to VGB and for another 
34.5% a probable relation to VGB was proposed. 
The fact that no special measure was needed in 
nearly 60% of the cases suggests that these were 
moderate and transient adverse events. In an 
additional 9% of cases, a reduction of dose was 
deemed to be sufficient. 
In the authors’ experience, the most common 
problem associated with VGB is drowsiness or 
sleep disorders. It rarely represents a serious 
problem, and in the majority of cases tolerance to 
this side-effect occurs after 1 or 2 weeks of 
treatment. As reported by Reynolds, the in- 
cidence of drowsiness can be minimized by 
progressive introduction of VGB”. Irritability 
and poor concentration are occasionally ob- 
served, but in our experience discontinuation of 
the drug is only seldomly required, as these 
effects usually respond to a reduction in dose. 
Data from the present study support the opinion 
that psychotic reactions are rare= with VGB and 
the few published cases23*24 mainly concerned 
patients with long-standing epilepsy and a history 
of severe psychiatric disturbance. Furthermore, 
the relationship between such phenomena and an 
abrupt complete control of seizures in patients 
with long-lasting severe epilepsies represents a 
complex nosological problem that remains to be 
elucidated. In patients with a history of severe 
psychiatric illness, cautious use of VGB is 
possible, but gradual introduction and an ade- 
quate follow-up are necessary. 
Exacerbation of seizure frequency may be 
observed with any AED, but is nevertheless a 
rare phenomenon. Some AEDs may have an 
aggravating effect in certain types of seizure. For 
example, carbamazepine and vigabatrin may 
exacerbate myoclonic seizure?. One patient in 
this study experienced such an effect following 
introduction of VGB. Although rare, this 
side-effect should be known as it may be observed 
in patients suffering from mixed seizure dis- 
orders, with several types of seizures. In our 
experience, these patients may benefit from VGB 
treatment but should be aware of the risk of 
exacerbation of myoclonic jerks that can be 
avoided by using the proper drug combination. 
Finally, some patients in this study reported 
weight gain. According to Tartara et al’, an 
increase of S-16% in initial body weight was 
observed in 40% of 25 patients over the first 3-6 
months of VGB treatment, thereafter tending to 
reach a plateau. In the present study, some weight 
gain was reported by 5.8% of the patients, but it 
was never considered sufficiently lmportant to 
merit discontinuation of VGB. In the authors’ 
experience, this percentage reflects what is 
usually observed. In extremely rare cases, pro- 
nounced weight gain may justify withdrawal of 
VGB. 
Ease of use 
Most of the investigators agreed that VGB was 
easy to use and stressed that lack of interactions 
facilitates its use in older patients with sympto- 
matic partial epilepsy, who are likely to be 
receiving other drugs, especially for cardiovascu- 
lar disorders. 
As VGB is not an enzyme inducer, addition of 
the drug to previous anti-epilepsy therapy permits 
a rapid evaluation of its efficacy and eventual 
side-effects, as no adjustment of the previous 
treatment is needed. This is often not the case for 
drugs with a high potential for interaction26J7. 
Finally, the fact that VGB does not interact with 
oral contraceptives is important, as few AEDs 
can be easily used in partial epilepsies for female 
patients receiving contraception. 
Easy titration is another advantage of VGB, 
compared with drugs for which introduction and 
adjustment of dose must be longer if one wants to 
avoid undesirable side-effects and test efficacy. 
Introduction of a VGB dose of 2 g/day is 
clinically possible from the first day of treatment. 
This may prove to be useful in certain circum- 
stances. However, the general principle of pro- 
gressive introduction of any AED is of value. 
Data from this study do not suggest that in 
everyday clinical practice it is necessary to take 
more than 2 weeks to introduce a VGB dose of 
230 A.A. Atzimanoglou et a/ 
2g/day. Furthermore, due to its mode of action, 
the general principles of slow withdrawal should 
be applied. 
During the study results review meetings, the 
fact that follow-up of patients receiving VGB is 
mainly clinical and that evaluation of blood VGB 
levels is not necessary engendered some discus- 
sions about the usefulness of monitoring AED 
levels. Such monitoring is undoubtedly a useful 
tool, especially for certain drugs. However, to 
respect the patient’s quality of life, it should 
always be remembered that ‘therapeutic’ and 
‘toxic’ levels can only be regarded individually, on 
the basis of clinical data. Ranges of ‘efficacy’ and 
‘toxicity’ for all AEDs are merely statistically 
established values and should be regarded as 
such. The mechanism of action of VGB renders a 
long titration period and determination of plasma 
drug concentrations unnecessary, thus reducing 
the overall cost of epilepsy care for a given 
patient. 
From the previous comments it is evident that, 
irrespective of the personal attitude of the 
prescriber (immediate vs. rapidly progressive 
introduction, once or twice daily administration) 
prescription of a drug that is easy to use, like 
VGB, reinforces the concept that in the case of 
well-controlled epilepsy, regular clinical supervi- 
sion is the only essential measure. 
CONCLUSIONS 
‘Having epilepsy is more than just having seizures 
and every effort should be made to help patients 
live as normal lives as possible and to support 
positively their involvement as full members of 
the community”‘. Treatment of epilepsies is 
always a reasonable compromise between bene- 
fits (i.e. control of seizures, improved quality of 
life) and risks (side-effects, drug interactions, 
etc.). In terms of efficacy, VGB has already 
passed successfully the notoriously difficult test 
of chronic epilepsy patients with severe epi- 
lepsies. After ten years of clinical use, adverse 
events have proved to be infrequent and, for the 
great majority of patients, transient. 
This open, prospective study suggests that 
VGB is effective and well-tolerated as add-on 
treatment in the routine management of patients 
with non-severe partial epilepsy. Control of 
secondary generalization was achieved in the 
vast majority of cases. As VGB is easy to use in 
everyday clinical practice, it has an important role 
in the early management of patients with 
uncontrolled partial seizures. Further studies are 
needed to establish rigorously the possibility of 
using VGB as a first-line drug for monotherapy. 
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